Conference abstract
HAGE-derived vaccines for the treatment of patients with TNBC patients that are predicted to have high risk of relapsed and poor survival rate, as assessed by a newly identified immune-gene signature
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Triple Negative Breast Cancer (TNBC) consists of very heterogeneous subgroups of breast cancers with significant clinical challenge, the prognosis and treatment of which remains poor and limited due to the lack of targeting structures for existing therapies. We hypothesised that disease recurrence and therapeutic resistance in those patients could be influenced/predicted by tumour-related immune-regulatory events that are reflected by changes in the immune phenotypes in the periphery. It is conceivable that the analysis of immune gene transcripts in the blood will inform clinical decisions and help predict which patients are likely to respond/benefit from chemo- and/or immune-therapy. Although, breast cancer has not traditionally been viewed as being particularly susceptible to immunotherapeutic approaches, recent evidence has demonstrated a role for immune surveillance in determining patient outcome. Moreover, recent data suggest that some patients with TNBC may benefit from immune-stimulating therapies that may act synergistically when combined with chemotherapeutic drugs and tumour vaccines targeting cancer specific antigens (CSAs) expressed in TNBC. We have found that the cancer testis antigen HAGE (DDX43, CT13) is expressed in 43% of patients with TNBC. In this study, we have assessed the potential value of a newly identified HAGE-derived vaccine, as administered using two different delivery systems, for the treatment of TNBC patients using pre-clinical models. We have also used the nanoString nCounterâ?¢ FLEX amplification-free gene profiling platform to determine whether the immune-related-gene profiles in the PBMC of TNBC patients could predict patients with high risk of recurrence and poor survival rate. We therefore propose that TNBC patients with such a gene profile may benefit from a HAGE-derived vaccine. PDF HTML
Keywords
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Allergy & Therapy
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Stephanie E McArdle”
- BylineArticles whose byline prints “Divya Nagarajan”
- BylineArticles whose byline prints “Gemma Foulds”
- BylineArticles whose byline prints “Lindy Durrant”
- BylineArticles whose byline prints “Dennis Christensen”
- BylineArticles whose byline prints “Stephen Y T Chan”
- BylineArticles whose byline prints “Sergio Rutella”
- BylineArticles whose byline prints “A Graham Pockley”
